QID 15152

QID 15152: ISC BIND Multiple Vulnerabilities (CVE-2023-50868)

ISC BIND (Berkley Internet Domain Name) is an implementation of DNS protocols.

Affected versions:
BIND 9.0.0 - 9.16.46
BIND 9.18.0 - 9.18.22
BIND 9.19.0 - 9.19.20
BIND Supported Preview Edition 9.9.3-S1 - 9.16.46-S1
BIND Supported Preview Edition 9.18.11-S1 - 9.18.22-S1

Patched Versions:
BIND 9.16.48
BIND 9.18.24
BIND 9.19.21
BIND Supported Preview Edition 9.16.48-S1
BIND Supported Preview Edition 9.18.24-S1

QID Detection Logic:
This unauthenticated check detects vulnerable systems by fetching the version information from the BIND service using banner.

By flooding the target resolver with queries exploiting this flaw an attacker can significantly impair the resolver's performance, effectively denying legitimate clients access to the DNS resolution service.

  • CVSS V3 rated as Critical - 9.8 severity.
  • CVSS V2 rated as High - 7.8 severity.
    • Solution
    Customers are advised to upgrade to the patched version latest release of CVE-2023-50868
    Workaround:
    Workaround:
    Although this is not recommended, disabling DNSSEC validation entirely will remove the vulnerability. We instead strongly advise installing one of the versions of BIND listed below, in which an exceptionally complex DNSSEC validation will no longer impede other server workload.

    Vendor References

    CVEs related to QID 15152

    CVE-2023-50868 |
    Software Advisories
    Advisory ID Software Component Link
    CVE-2023-50868 URL Logo kb.isc.org/docs/cve-2023-50868
    By selecting these links, you may be leaving CVEreport webspace. We have provided these links to other websites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other websites that are more appropriate for your purpose. CVEreport does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, CVEreport does not endorse any commercial products that may be mentioned on these sites. Please address comments about any linked pages to [email protected].